US 12,427,202 B2
Compositions and methods of treating muscle dystrophy
Venkata Ramana Doppalapudi, San Diego, CA (US); Michael David Hood, San Diego, CA (US); Rob Burke, Encinitas, CA (US); Michael Caramian Cochran, San Diego, CA (US); Beatrice Diana Darimont, San Diego, CA (US); Yunyu Shi, La Jolla, CA (US); Gulin Erdogan Marelius, San Diego, CA (US); and Barbora Malecova, La Jolla, CA (US)
Assigned to AVIDITY BIOSCIENCES, INC., San Diego, CA (US)
Filed by Avidity Biosciences, Inc., San Diego, CA (US)
Filed on May 31, 2023, as Appl. No. 18/326,903.
Application 18/326,903 is a continuation of application No. 17/818,319, filed on Aug. 8, 2022, granted, now 11,707,532.
Application 17/818,319 is a continuation of application No. 17/214,525, filed on Mar. 26, 2021, granted, now 11,446,387, issued on Sep. 20, 2022.
Claims priority of provisional application 63/001,211, filed on Mar. 27, 2020.
Prior Publication US 2023/0398231 A1, Dec. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); C12N 15/113 (2010.01)
CPC A61K 47/6807 (2017.08) [A61K 47/6849 (2017.08); C12N 15/1137 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3513 (2013.01)] 9 Claims
 
1. A polynucleic acid molecule that hybridizes to a target sequence of DMPK mRNA comprising:
a sense strand comprising the nucleic acid sequence of SEQ ID NO: 1; and
an antisense strand comprising the nucleic acid sequence of SEQ ID NO: 2, wherein the antisense strand comprises 2′-F modified nucleotides at positions 2, 6, 14, and 16 from the 5′-end.